RADIOBOTICS APS

Their core work

Radiobotics is a Copenhagen-based health technology company that builds AI software for automated analysis of musculoskeletal X-rays — think knee, hip, shoulder, and spine images read by an algorithm rather than waiting for a radiologist. Their core product automates the reporting pipeline for routine orthopedic imaging, reducing turnaround time and radiologist workload. The company is grounded in deep learning applied to medical imaging data, with a commercial focus on deploying this technology in clinical settings. They are a product company, not a research lab — their H2020 funding was used to develop and scale a market-ready solution.

What they specialise in

How they've shifted over time

Radiobotics has a short but focused H2020 trajectory — both projects carry the same name (AutoRay) and the same objective, which tells a clear story of deliberate product development rather than exploratory research. In the Phase 1 feasibility study (2019), no specific technical keywords were recorded, suggesting the work was still at the conceptual and business case stage. By Phase 2 (2020–2023), the keywords crystallize into a concrete technical stack: deep learning, radiology automation, and data-driven health technology applied to musculoskeletal X-rays. There is no pivot or shift in domain — this organization found its niche early and went deeper, which is typical of a focused product company scaling through EU SME Instrument funding.

Radiobotics is on a commercialization trajectory — having completed both Phase 1 and Phase 2 of the SME Instrument, they are likely past the R&D stage and focused on clinical adoption, regulatory clearance, and scaling their AutoRay product across European radiology departments.

How they like to work

Radiobotics operates exclusively as a project coordinator and has no recorded consortium partners in H2020 — both AutoRay projects were single-entity SME Instrument grants, which is structurally normal for that funding scheme. This means they are not experienced in multi-partner consortium management, and there is no track record of how they function as a partner within a larger project. For future collaborations, they are most likely to join as a technology provider or clinical AI specialist rather than as a consortium architect.

Radiobotics has no recorded H2020 consortium partners, which is a direct consequence of the SME Instrument funding model rather than a sign of isolation. Their real-world network likely includes clinical partners and hospital systems in Denmark and Scandinavia, but this is not visible in the H2020 data.

What sets them apart

Radiobotics occupies a narrow but commercially valuable niche: automated AI reporting specifically for musculoskeletal radiology, a subspecialty with high imaging volume and chronic radiologist shortages across Europe. Unlike general medical imaging AI companies, they are focused on a single modality (X-ray) and a single clinical domain (orthopedics/MSK), which makes their solution easier to validate, certify, and integrate into existing radiology workflows. For a consortium needing a clinical AI partner with a working product in orthopedic imaging, Radiobotics offers demonstrated technical depth and a completed EU-funded development cycle.

Highlights from their portfolio

• AutoRay
  The Phase 2 AutoRay grant (€1,333,816, 2020–2023) is notable for being a full SME Instrument Phase 2 award — one of the most competitive EU grants for single-company product development — validating both the technology and the commercial case for automated musculoskeletal X-ray reporting.
• AutoRay
  The Phase 1 AutoRay grant (2019) demonstrates a textbook SME Instrument progression: Radiobotics used the €50,000 feasibility study to secure the larger Phase 2 award, showing strategic use of EU funding instruments rather than opportunistic application.